Committed to the Future of Antibiotics

News
4 October 2017

Visit our Poster Showing Prevention of C. diff Induced Death at IDWeek 2017

Da Volterra will present a poster at IDWeek 2017 in San Diego (...)

22 September 2017

Da Volterra announces 20M€ from EIB to advance clinical development against antibiotic resistance

We are pleased to announce that the European Investment Bank (...)

7 September 2017

Da Volterra will Present in the C.diff Foundation Science Webinar September 14th, 2017

Da Volterra is looking forward to the C. diff Foundation (...)

4 September 2017

Da Volterra Demonstrates Prevention of Clostridium difficile Induced Death

Da Volterra, a biotechnology company located in Paris, France, (...)

Who we are

Da Volterra:
Committed to the Future of Antibiotics

Da Volterra is a biotechnology company developing a portfolio of unique products in the antibacterial field, with a specific focus on antibiotic resistance.

Our most advanced product is DAV132, developed to prevent the disruption of the intestinal microbiota and prevent Clostridium difficile infections associated with antibiotic use. Discover DAV132 in the video below:

DAV132 has already undergone three phase I clinical trials. It has been developed using in-house expertise on resistant gut microbiomes and proprietary drug delivery technologies. Learn more >

500,000 Americans infected
by Clostridium difficile
each year

Learn more >

 

Developpeur PHP Drupal